SecBot SecBot
8-K ·Filed May 13, 2026

PGEN

PRECIGEN, INC.
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0000950103-26-007158
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The PAPZIMEOS launch is accelerating faster than expected, with Q1 revenue already exceeding the prior quarter's full-year total. The permanent J-code taking effect in April should further boost site activations and patient starts in Q2. Watch for continued revenue growth and progress toward cash flow break-even by year-end. The upcoming ASCO presentation (May 29-June 2) may provide additional catalyst on durability data.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$4.60
T+0 close · May 13, 2026 · via day close
Latest settled
+52.17%
T+60 · $7.00
Vs SPY
+48.59%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 14 $4.60entry
  2. T+1 · 6mo ago 0.00%α −0.01% · $4.60
  3. T+5 · 6mo ago −6.96%α −6.24% · $4.28
  4. T+20 · 5mo ago −3.26%α −2.40% · $4.45
  5. T+60 · 3mo ago +52.17%α +48.59% · $7.00
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Precigen reported Q1 2026 revenue of $23.3M, massively up from $1.3M a year ago, driven by $21.6M in PAPZIMEOS product revenue in its first full commercial quarter. Net loss narrowed to $7.9M ($0.02/share) from $54.2M ($0.18/share) in Q1 2025, as the company transitions to a commercial-stage biopharma. The strong launch trajectory and cash position of $56.7M support management's expectation of reaching cash flow break-even by end of 2026.

Key Financial Metrics

EPS
−$0.02
est −$0.03 · +33.3%
Revenue
$23.3M
est $20.8M · +11.8% · +1633.9% YoY
Rating
strong beat

Key Facts

  • Q1 2026 total revenue of $23.3M, up from $1.3M in Q1 2025, driven by $21.6M in PAPZIMEOS net product revenue
  • Net loss narrowed to $7.9M ($0.02/share) from $54.2M ($0.18/share) in Q1 2025
  • Cash, cash equivalents, and investments totaled $56.7M as of March 31, 2026
  • Approximately $25.7M in PAPZIMEOS-related accounts receivable not yet collected as of quarter-end
  • Company expects current cash plus anticipated PAPZIMEOS revenue to fund operations to cash flow break-even by end of 2026
  • Patient hub enrollment surpassed 400 patients, with 25% from community settings
  • Permanent J-code (J3404) effective April 1, 2026, expected to further streamline reimbursement and site activations

Financial Impact

Q1 2026 product revenue of $21.6M vs $0.2M in Q1 2025; net loss improved by $46.3M year-over-year

revenuenet losscash position

Risk Factors

  • Dependence on single product PAPZIMEOS for revenue; any commercial disruption would be material
  • Cash burn remains significant; break-even timeline depends on continued revenue acceleration
  • Long-term debt of $93.5M adds financial leverage and interest expense

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
78% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000950103-26-007158
Document: dp246650_8k.htm0000950103-26-007158
Document: 0000950103-26-007158-index-headers.html0000950103-26-007158
Document: 0000950103-26-007158-index.html0000950103-26-007158
Document: 0000950103-26-007158.txt0000950103-26-007158
8-K Data (Synthetic)0000950103-26-007158

Track record

13 reports on PGEN

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +10.43% at T+5 after the Nov 4, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 4, 202612d ago 8-K Bullish 6/10 Entry $4.22 to $4.66 Now $4.30 +1.90% ▲ +10.43% +7.14% vs SPY
  2. Aug 28, 202611w ago Insider Cluster Neutral 3/10 Entry $6.93 to $6.99 Now $4.30 −37.95% ▲ +0.79% +0.94% vs SPY
  3. Aug 26, 202611w ago 144 Neutral 3/10 Entry $7.19 to $7.14 Now $4.30 −40.19% ▼ −0.70% −0.96% vs SPY
  4. Aug 25, 202611w ago Insider Cluster Bearish 4/10 Entry $7.42 to $7.01 Now $4.30 +42.05% ▲ +5.53% +5.41% vs SPY
  5. Aug 25, 202611w ago Insider Cluster Neutral 2/10 Entry $7.42 to $7.01 Now $4.30 −42.05% ▼ −5.53% −5.41% vs SPY
  6. Aug 7, 202614w ago Insider Cluster Neutral 2/10 Entry $7.00 to $6.55 Now $4.30 −38.57% ▼ −6.43% −6.38% vs SPY
  7. Aug 3, 202615w ago Insider Cluster Neutral 2/10 Entry $6.53 to $6.86 Now $4.30 −34.15% ▲ +5.05% +5.15% vs SPY
  8. Jul 1, 202619w ago Insider Cluster Bearish 5/10 Entry $5.64 to $5.53 Now $4.30 +23.76% ▲ +1.95% +2.88% vs SPY
  9. Jun 24, 202620w ago 8-K Neutral 3/10 Entry $5.52 to $5.25 Now $4.30 −22.10% ▼ −4.89% −6.45% vs SPY
  10. Jun 1, 202624w ago Insider Cluster Neutral 3/10 Entry $3.86 to $3.71 Now $4.30 +11.40% ▼ −3.89% −0.92% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 13, 2026